GeoVax Corp (GOVX): Average Forecast Price
GeoVax Labs, Inc. (GOVX) relies on outsourcing clinical trials to third-party contractors, which minimizes internal risks. The development of oncology and viral vaccines ensures a multi-year cash flow for the company through patents. This trading chart captures the 240.46 indicator. Growth prospects depend on US government subsidies, the licensing of the GV-MVA-VLP platform, and the trial results of drugs targeting coronaviruses and head neoplasms.
Analytical breakdowns for GeoVax Labs Inc (GOVX)
- market value and analyst target forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Aggregate Debt to Equity GeoVax Labs, Inc.|GOVX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital GeoVax Corp|GOVX - Company Aggregate Debts|Debts to Book Capitalization GeoVax Labs Inc|GOVX - Company Long-Term Debt|Company Short-Term Loans and Borrowings GeoVax|Quick Liquidity Indicator geovax.com
- financial results and valuation multiples details:
GOVX - Net Profit|Projected Future Earnings GeoVax Labs, Inc.|GOVX - Price to Earnings Ratio|Future Price to Earnings Multiple GeoVax Labs|GOVX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio GeoVax Labs Inc|GOVX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months GeoVax|GOVX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months geovax.com|GOVX - Net earnings per share growth this year|Earnings growth forecast for next year GeoVax Labs, Inc.
General company analysis:GOVX geovax.com
The potential of GeoVax Labs, Inc. (GOVX) depends on the outcomes of clinical trials for vaccines targeting underserved cancer therapy and infectious disease markets. The average investment bank forecast, reflected in the current consensus target price, determines the asset's fair value, allowing investors to promptly assess revisions to the company's fundamental value in response to new medical data and market cycles.
Competitors of GeoVax Labs, Inc.
argenx.com (ARGX) - Analyst Target Range|Price Target Chart BioNTech BNTX|Abivax SA (ABVX) - Average Forecast Price|ADMA: Consensus Target|PTGX: Price Target Chart|IMVT (Immunovant, Inc.) - Consensus Target|Broker Consensus Forecast KNSA|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|Analyst Target Range Aclaris Therapeutics, Inc (ACRS)|KYTX: Analyst Consensus Forecast|Average Forecast Price tizianalifesciences.com (TLSA)|Price Target Chart Cabaletta Bio|Average Forecast Price Ventyx Biosciences Inc. VTYX|Consensus Target THTX (Theratechnologies Inc)|Price Target Chart AVTX (Avalo Therapeutics Inc)|Analyst Consensus Forecast ELDN (Eledon Pharmaceuticals)|Analyst Consensus Forecast agenusbio.com AGEN|CLYM: Consensus Target|ZURA (zurabio.com) - Broker Consensus Forecast|ATYR (aTyr) - Consensus Target|Adagene Inc. - Fair Value Consensus|Price Target Chart ImageneBio|Price Target Chart STTK|Analyst Consensus Forecast EQ|Analyst Consensus Forecast connectbiopharm.com (CNTB)|Analyst Consensus Forecast IMUX (Immunic)|Atara Biotherapeutics, Inc. - Price Target Chart|IFRX - Price Target Chart|Analyst Median Target x4pharma.com XFOR|ACET (adicetbio.com) - Consensus Target|Celularity - Fair Value Consensus|INMB (INmune Bio Corp) - Analyst Consensus Forecast|Barinthus Biotherapeutics Corp (BRNS) - Analyst Median Target|Price Target Chart Kezar Life Sciences (KZR)|sabbiotherapeutics.com - Broker Consensus Forecast|Analyst Consensus Forecast AKTX (Akari Therapeutics Plc)|ENLV - Consensus Target|QTTB: Consensus Target|Analyst Median Target Edesa Biotech Corp EDSA|IBIO: Analyst Consensus Forecast|Analyst Target Range Carisma Therapeutics Inc. CARM|Price Target Chart XTL Biopharmaceuticals Ltd.|Average Forecast Price Bolt Bio BOLT|Consensus Target HCWB (HCW Biologics Inc.)|Price Target Chart APVO (aptevotherapeutics.com)|AIM ImmunoTech - Consensus Target|ADTX: Broker Consensus Forecast|GRI - Price Target Chart|Forecast Levels Chart XRTX|HIND: Analyst Consensus Forecast|Revelation Biosciences Corp - Fair Value Consensus|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|Analyst Consensus Forecast scinai.com|Price Target Chart CalciMedica, Inc. (CALI)|AFMD (affimed.com) - Fair Value Consensus|Price Target Chart Allakos ALLK|HOOK - Consensus Target|IGM Bio - Analyst Consensus Forecast|ITOS - Analyst Consensus Forecast|OCEA (Ocean Biomedical) - Consensus Target|TC BioPharm (Holdings) Plc - Fair Value Consensus|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
